UK Health Secretary James Murray tells Parliament he is uneasy about a proposed clinical trial involving puberty blockers for children, citing a lack of clinical evidence about the risks and benefits. MPs raise concerns about what support would be available for patients if they later stop or detransition, and they question whether adequate safeguards and follow-up care are in place. Murray acknowledges the evidence gap and says the trial should proceed only “carefully,” with close oversight and “intense scrutiny.” The discussion focuses on ensuring the trial is appropriately monitored and that any potential impacts on participants are properly assessed. While Murray backs moving forward with the study under stringent conditions, MPs continue to press for clarity about evidence standards and the availability of clinical support beyond the trial period. The parliamentary exchange highlights disagreement over the balance between proceeding with research and addressing concerns about uncertainty and patient welfare.